SOPHARMA AD - Decisions taken at the Extraordinary General Meeting of Shareholders of Sopharma AD, held on 23.02.2018

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 9 / 2018

Date of issue: 2018-02-23

Short name of the issuer

SOPHARMA AD

Subject

Decisions taken at the Extraordinary General Meeting of Shareholders of Sopharma AD, held on 23.02.2018

Official market - legal basis

art. 56. 1. 2 of Act on Public Offering.

Unofficial market - legal basis

Contents of the report:

Sopharma AD notifies that on 23.02.2018 an Extraordinary general meeting of shareholders took place. The General meeting of shareholders approved the decision for transformation of Sopharma AD, UIC: 831902088 by merging Unipharm AD, UIC: 831537465 into it. As a result of the merger, the entire property of Unipharm AD, UIC: 831537465 will be transferred to Sopharma AD, UIC: 831902088 under the conditions of general succession. The General meeting of shareholders approved the Contract for transformation through merger of Unipharm AD into Sopharma AD, concluded on 14.09.2017, Additional Agreement No. 1 of 08.11.2017 to it (the "Contract for transformation through merger "). The General meeting of shareholders approved the Report of the Board of Directors of Sopharma AD to the shareholders of the company regarding the transformation through merger of Unipharm AD into Sopharma AD. The General meeting of shareholders approved the Auditor's Report under Art. 262m of the CA on the transformation through merger of Unipharm AD into Sopharma AD. The General meeting of shareholders approved changes in the Company's Articles of Association which allows the payment of an interim dividend on the basis of a 6-month financial statement under the Public Offering of Securities Act. The General Meeting of Shareholders, on the grounds of Art.187b of the Commercial Law and Art.111, para 5 of POSA, approved a resolution for the acquisition of own shares from the capital of the Company under the following conditions: up to 10% of the total number of shares issued by the company, but not more than 3% in each calendar year; term of the acquisition - no longer than 5 (five) years; minimum price for acquisition - not less than the nominal value per share of the company's capital; maximum price for acquisition - BGN 5.50 per share; The minutes of the General Meeting of Shareholders of Sopharma AD, held on 23.02.2018, will be sent to you within the statutory term. All conversion documents are available as part of the materials of the extraordinary general meeting.

Annexes

File Description

3JR_2018_EGM_Decisions_EN.docx Decisions taken at the Extraordinary General Meeting of Shareholders of Sopharma AD, held on 23.02.2018

SOPHARMA AD

(fullname of the issuer)

SOPHARMA AD Farmaceutyczny (far)

(short name of the issuer) (sector according to clasification of the WSE in Warsow)

1220 Sofia

(post code) (city)

IlienskoShosse 16

(street) (number)

[phone] [phone]

(phone number) (fax)

(e-mail) (web site)

nd

(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Date Name Position / Function Signature

2018-02-23 Ognian Donev Executive director